AR067775A1 - (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso - Google Patents
(2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de usoInfo
- Publication number
- AR067775A1 AR067775A1 ARP080103348A ARP080103348A AR067775A1 AR 067775 A1 AR067775 A1 AR 067775A1 AR P080103348 A ARP080103348 A AR P080103348A AR P080103348 A ARP080103348 A AR P080103348A AR 067775 A1 AR067775 A1 AR 067775A1
- Authority
- AR
- Argentina
- Prior art keywords
- trazodone
- piridinil
- azabiciclo
- benzofuran
- carboxamide
- Prior art date
Links
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 abstract 5
- 229960002301 trazodone hydrochloride Drugs 0.000 abstract 5
- 229960003991 trazodone Drugs 0.000 abstract 4
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000008346 aqueous phase Substances 0.000 abstract 2
- 239000012074 organic phase Substances 0.000 abstract 2
- 230000002152 alkylating effect Effects 0.000 abstract 1
- 150000007514 bases Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95361407P | 2007-08-02 | 2007-08-02 | |
| US95361007P | 2007-08-02 | 2007-08-02 | |
| US95361307P | 2007-08-02 | 2007-08-02 | |
| US97165407P | 2007-09-12 | 2007-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067775A1 true AR067775A1 (es) | 2009-10-21 |
Family
ID=39945177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103348A AR067775A1 (es) | 2007-08-02 | 2008-08-01 | (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso |
Country Status (35)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US20110098312A1 (en) * | 2008-05-12 | 2011-04-28 | Targacept ,Inc | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| PE20170923A1 (es) | 2010-05-17 | 2017-07-12 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado |
| BR112013001939A2 (pt) * | 2010-07-26 | 2017-07-11 | Envivo Pharmaceuticals Inc | tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase |
| PE20131394A1 (es) | 2010-09-23 | 2014-01-11 | Abbvie Inc | Monohidrato de derivados de aza-adamantano |
| CA2824900A1 (en) * | 2011-01-18 | 2012-07-26 | Targacept, Inc. | Treatment of cognitive dysfunction in schizophrenia |
| WO2012101060A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
| AU2012232711B2 (en) | 2011-03-18 | 2016-04-28 | Novartis Ag | Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease |
| WO2012129262A1 (en) * | 2011-03-23 | 2012-09-27 | Targacept, Inc. | Treatment of attention deficit/hyperactivity disease |
| BR112013032044A2 (pt) | 2011-06-30 | 2016-12-13 | Toray Industries | antiprurítico |
| TW201311698A (zh) * | 2011-08-22 | 2013-03-16 | Targacept Inc | 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷 |
| ES2776996T3 (es) | 2011-10-20 | 2020-08-03 | Novartis Ag | Biomarcadores predictivos de la sensibilidad al tratamiento por el activador del receptor de la acetilcolina nicotínico alfa 7 |
| ES2950418T3 (es) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden alcohol bencílico |
| JP6219918B2 (ja) * | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
| ES2765036T3 (es) | 2012-03-19 | 2020-06-05 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden esteres de ácidos grasos |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| EP2897592B1 (en) | 2012-09-19 | 2020-02-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| CN104837499B (zh) | 2012-12-11 | 2018-02-23 | 诺华有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物 |
| MX362819B (es) * | 2013-01-15 | 2019-02-18 | Novartis Ag | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia. |
| JP6338223B2 (ja) | 2013-01-15 | 2018-06-06 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体アゴニストの使用 |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| KR101879919B1 (ko) | 2013-01-15 | 2018-07-18 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도 |
| WO2014153424A1 (en) * | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN104288771B (zh) * | 2014-09-30 | 2017-03-15 | 郑州大学第五附属医院 | α7nAChR激动剂的新用途 |
| AU2016258192B2 (en) | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| US9724340B2 (en) * | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| US10282666B1 (en) | 2015-11-10 | 2019-05-07 | Google Llc | Coherency detection and information management system |
| RU2675111C2 (ru) * | 2017-03-31 | 2018-12-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" | Способ стимуляции нейрогенеза в гиппокампе |
| EP3612526A2 (en) | 2017-04-20 | 2020-02-26 | The Regents of the University of California | K-ras modulators |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203990A (en) | 1979-04-30 | 1980-05-20 | G. D. Searle & Co. | Anti-diarrheal 2-substituted quinuclidines |
| EP0353189B1 (de) | 1988-07-28 | 1994-01-12 | Ciba-Geigy Ag | Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| EP0402056A3 (en) | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| EP0412798A3 (en) | 1989-08-08 | 1992-07-01 | Merck Sharp & Dohme Ltd. | Substituted pyridines, their preparation, formulations and use in dementia |
| IN173570B (https=) | 1989-11-23 | 1994-06-04 | Pfizer | |
| DK40890D0 (da) | 1990-02-16 | 1990-02-16 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
| EP0492903A1 (en) | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma |
| EP0573568B1 (en) | 1991-03-01 | 2001-01-24 | University Of Florida Research Foundation, Inc. | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| US5276043A (en) | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| KR100272614B1 (ko) * | 1992-08-31 | 2000-11-15 | 엠. 잭 오해니언 | 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체 |
| US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| IL109451A0 (en) * | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
| AU7474794A (en) | 1993-07-22 | 1995-02-20 | E.I. Du Pont De Nemours And Company | Arthropodicidal azacyclic heterocycles |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5510355A (en) | 1994-09-06 | 1996-04-23 | Bencherif; Merouane | Depolarizing skeletal muscle relaxants |
| US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5824692A (en) | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| JPH11500113A (ja) | 1995-02-17 | 1999-01-06 | ノボ ノルディスク アクティーゼルスカブ | ヘテロ環化合物類の使用 |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| WO1997001556A1 (en) | 1995-06-29 | 1997-01-16 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
| JPH11512443A (ja) | 1995-09-22 | 1999-10-26 | ノボ ノルディスク アクティーゼルスカブ | 新規な置換アザ環式またはアザ二環式化合物 |
| US5712270A (en) | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| KR100589872B1 (ko) | 1997-05-30 | 2006-06-15 | 뉴로서치 에이/에스 | 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| WO1999051602A1 (en) | 1998-04-02 | 1999-10-14 | R.J. Reynolds Tobacco Company | Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them |
| DK1083889T3 (da) | 1998-06-01 | 2004-04-13 | Ortho Mcneil Pharm Inc | Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| GB9821503D0 (en) | 1998-10-02 | 1998-11-25 | Novartis Ag | Organic compounds |
| US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| US6734215B2 (en) | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| FR2791678B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| KR100751981B1 (ko) | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | 아릴알킬아민으로부터 유도된 카바메이트 |
| AU2001284645A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6479510B2 (en) | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| WO2002016357A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002016355A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| NZ526580A (en) | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| BR0210075A (pt) | 2001-06-01 | 2004-08-17 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| AR036040A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| US7109204B2 (en) | 2001-08-01 | 2006-09-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2458375A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease |
| JP2005504059A (ja) | 2001-08-24 | 2005-02-10 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | 疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン |
| DE60218493D1 (de) | 2001-09-12 | 2007-04-12 | Pharmacia & Upjohn Co Llc | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| NZ561993A (en) | 2002-04-18 | 2008-09-26 | Astrazeneca Ab | Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors |
| ES2348282T3 (es) | 2002-04-18 | 2010-12-02 | Astrazeneca Ab | Compuestos de tienilo. |
| US7417049B2 (en) | 2002-04-18 | 2008-08-26 | Astrazeneca Ab | Furyl compounds |
| US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| WO2004016608A1 (en) | 2002-08-14 | 2004-02-26 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
| SE0202465D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| US7244745B2 (en) | 2002-08-30 | 2007-07-17 | Memory Pharmaceuticals Corp. | Heterocyclic compounds, methods for the preparation thereof, and uses thereof |
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| WO2004039815A2 (en) | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases |
| AU2003269413A1 (en) | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| JP4750421B2 (ja) | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | α７受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
| AP2005003336A0 (en) | 2002-12-11 | 2005-06-30 | Pharmacia & Upjohn Co Llc | Combination for the treatment of ADHD |
| PL377777A1 (pl) | 2002-12-11 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków |
| US6917746B2 (en) | 2002-12-17 | 2005-07-12 | 3M Innovative Properties Company | Apparatus and method for creating a fiber optic circuit |
| US6777617B2 (en) | 2002-12-30 | 2004-08-17 | 3M Innovative Properties Company | Telecommunications terminal |
| DE602004023586D1 (de) | 2003-02-27 | 2009-11-26 | Neurosearch As | Neue diazabicyclische arylderivate |
| CN1829721A (zh) | 2003-07-08 | 2006-09-06 | 阿斯利康(瑞典)有限公司 | 对α7烟碱乙酰胆碱受体具有亲和力的螺[1－氮杂二环[2.2.2]辛烷－3,5’－噁唑烷]－2’－酮衍生物 |
| AU2004276061A1 (en) | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Ligands |
| BRPI0415546A (pt) | 2003-10-21 | 2006-12-26 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios |
| US20050137398A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
| US20050137217A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | Spirocyclic quinuclidinic ether derivatives |
| US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| JP2007520527A (ja) * | 2004-02-04 | 2007-07-26 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体 |
| CA2567977A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| NZ551712A (en) | 2004-05-07 | 2010-07-30 | Memory Pharm Corp | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof |
| ATE493415T1 (de) * | 2004-10-20 | 2011-01-15 | Neurosearch As | Neue diazabizyklische arylderivate und medizinische verwendung dafür |
| MX2007006743A (es) | 2004-12-15 | 2007-07-09 | Astrazeneca Ab | Ligandos del receptor de acetilcolina nicotinica. |
| CA2591817A1 (en) * | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| EP1891036A4 (en) | 2005-06-07 | 2010-08-04 | Univ Florida | SELECTIVE LIGANDS FOR ALPHA-7 NICOTINE RECEPTORS |
| US7732607B2 (en) | 2005-08-22 | 2010-06-08 | Anatoly Mazurov | Heteroaryl-substituted diazatricycloalkanes and methods of use thereof |
| CN101312968A (zh) | 2005-09-23 | 2008-11-26 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途 |
| US8316104B2 (en) * | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| KR20100113163A (ko) * | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
-
2008
- 2008-07-03 SA SA08290475A patent/SA08290475B1/ar unknown
- 2008-07-31 TW TW102135271A patent/TW201402116A/zh unknown
- 2008-07-31 TW TW097129030A patent/TWI429435B/zh not_active IP Right Cessation
- 2008-07-31 TW TW102135272A patent/TW201402117A/zh unknown
- 2008-08-01 US US12/674,327 patent/US20110124678A1/en not_active Abandoned
- 2008-08-01 US US12/184,312 patent/US7981906B2/en active Active
- 2008-08-01 PE PE2008001292A patent/PE20090566A1/es not_active Application Discontinuation
- 2008-08-01 RS RS20130115A patent/RS52743B/sr unknown
- 2008-08-01 MX MX2012009257A patent/MX346451B/es unknown
- 2008-08-01 EP EP11194142.3A patent/EP2431037B1/en active Active
- 2008-08-01 NZ NZ582828A patent/NZ582828A/en not_active IP Right Cessation
- 2008-08-01 PE PE2012000921A patent/PE20121821A1/es not_active Application Discontinuation
- 2008-08-01 MX MX2010001293A patent/MX2010001293A/es not_active Application Discontinuation
- 2008-08-01 SI SI200830931T patent/SI2182949T1/sl unknown
- 2008-08-01 EP EP11194161.3A patent/EP2465501B1/en active Active
- 2008-08-01 CA CA2694510A patent/CA2694510A1/en not_active Abandoned
- 2008-08-01 JP JP2010520219A patent/JP2010535252A/ja active Pending
- 2008-08-01 CA CA2694504A patent/CA2694504C/en not_active Expired - Fee Related
- 2008-08-01 EP EP12164661A patent/EP2484363A1/en not_active Withdrawn
- 2008-08-01 AU AU2008283813A patent/AU2008283813A1/en not_active Abandoned
- 2008-08-01 EP EP08782589A patent/EP2185152A2/en not_active Withdrawn
- 2008-08-01 PL PL08782584T patent/PL2182949T3/pl unknown
- 2008-08-01 BR BRPI0814889A patent/BRPI0814889A2/pt not_active IP Right Cessation
- 2008-08-01 KR KR1020107004202A patent/KR20100063043A/ko not_active Withdrawn
- 2008-08-01 DK DK11194142.3T patent/DK2431037T3/en active
- 2008-08-01 CN CN200880101593A patent/CN101868237A/zh active Pending
- 2008-08-01 SA SA112330303A patent/SA112330303B1/ar unknown
- 2008-08-01 AR ARP080103348A patent/AR067775A1/es not_active Application Discontinuation
- 2008-08-01 HU HUE11194142A patent/HUE030387T2/en unknown
- 2008-08-01 KR KR1020107004216A patent/KR20100051684A/ko not_active Ceased
- 2008-08-01 CN CN200880103971.1A patent/CN101784273B/zh not_active Expired - Fee Related
- 2008-08-01 PE PE2012000920A patent/PE20121820A1/es not_active Application Discontinuation
- 2008-08-01 UY UY0001031265A patent/UY31265A/es not_active Application Discontinuation
- 2008-08-01 ES ES08782584T patent/ES2415107T3/es active Active
- 2008-08-01 EP EP11075209A patent/EP2409703A1/en not_active Withdrawn
- 2008-08-01 AU AU2008283807A patent/AU2008283807B2/en not_active Ceased
- 2008-08-01 CL CL2008002271A patent/CL2008002271A1/es unknown
- 2008-08-01 ME MEP-2013-28A patent/ME01508B/me unknown
- 2008-08-01 NZ NZ582986A patent/NZ582986A/en not_active IP Right Cessation
- 2008-08-01 WO PCT/US2008/071893 patent/WO2009018511A2/en not_active Ceased
- 2008-08-01 PT PT87825840T patent/PT2182949E/pt unknown
- 2008-08-01 ES ES11194161.3T patent/ES2606752T3/es active Active
- 2008-08-01 WO PCT/US2008/071872 patent/WO2009018505A1/en not_active Ceased
- 2008-08-01 PH PH1/2012/501514A patent/PH12012501514A1/en unknown
- 2008-08-01 PH PH1/2012/501513A patent/PH12012501513A1/en unknown
- 2008-08-01 JP JP2010520213A patent/JP5358573B2/ja active Active
- 2008-08-01 HR HRP20130286AT patent/HRP20130286T1/hr unknown
- 2008-08-01 CN CN2013100489009A patent/CN103172628A/zh active Pending
- 2008-08-01 CN CN201611140124.5A patent/CN106831755A/zh active Pending
- 2008-08-01 DK DK08782584.0T patent/DK2182949T3/da active
- 2008-08-01 ES ES11194142.3T patent/ES2611139T3/es active Active
- 2008-08-01 MX MX2012009258A patent/MX346748B/es unknown
- 2008-08-01 BR BRPI0815009-5A2A patent/BRPI0815009A2/pt not_active IP Right Cessation
- 2008-08-01 EP EP08782584A patent/EP2182949B1/en active Active
- 2008-08-01 MY MYPI2010000501A patent/MY148002A/en unknown
-
2010
- 2010-01-18 NO NO20100078A patent/NO20100078L/no not_active Application Discontinuation
- 2010-01-18 NO NO20100077A patent/NO20100077L/no not_active Application Discontinuation
- 2010-01-29 ZA ZA2010/00719A patent/ZA201000719B/en unknown
- 2010-03-02 CO CO10024587A patent/CO6260081A2/es not_active Application Discontinuation
- 2010-03-02 CO CO10024579A patent/CO6260080A2/es not_active Application Discontinuation
- 2010-03-02 EC EC2010010007A patent/ECSP10010007A/es unknown
- 2010-03-02 EC EC2010010008A patent/ECSP10010008A/es unknown
-
2011
- 2011-05-26 US US13/116,080 patent/US8541446B2/en active Active
- 2011-05-26 US US13/116,163 patent/US8119659B2/en active Active
-
2012
- 2012-04-02 IL IL218976A patent/IL218976A0/en not_active IP Right Cessation
- 2012-06-04 AU AU2012203288A patent/AU2012203288B2/en not_active Ceased
- 2012-09-19 RU RU2012140148/15A patent/RU2012140148A/ru not_active Application Discontinuation
- 2012-09-19 RU RU2012140182/15A patent/RU2012140182A/ru not_active Application Discontinuation
-
2013
- 2013-01-30 CY CY20131100081T patent/CY1113561T1/el unknown
- 2013-07-17 JP JP2013148087A patent/JP5852611B2/ja active Active
- 2013-07-17 JP JP2013148091A patent/JP6106549B2/ja active Active
- 2013-07-22 US US13/947,157 patent/US8846715B2/en active Active
- 2013-08-02 CL CL2013002227A patent/CL2013002227A1/es unknown
- 2013-08-02 CL CL2013002226A patent/CL2013002226A1/es unknown
-
2014
- 2014-08-25 US US14/467,289 patent/US20150045386A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067775A1 (es) | (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso | |
| AR067773A1 (es) | Trazodona e hidrocloruro de trazodona en forma purificada | |
| AR121611A2 (es) | Inhibidores de glucosilceramida sintasa | |
| BRPI0906786A2 (pt) | Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit. | |
| BRPI0610495A2 (pt) | compostos, processo para preparar os compostos, composição herbicida, e, método de controlar gramas e ervas daninhas em lavoura de plantas úteis | |
| BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
| BRPI0817597A2 (pt) | Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos | |
| BRPI0719879A8 (pt) | sal de adição de ácido, processo para sua preparação e seu uso, bem como intermediário químico | |
| GT200600420A (es) | Sales novedosas de lisina de derivados de acido 4-((fenoxialquil)tio)-fenoxiacetico | |
| BRPI0811275A2 (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença | |
| BRPI0812521A2 (pt) | Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto | |
| NO20090173L (no) | Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes | |
| BRPI0908738A2 (pt) | composto, medicamento, uso de um composto, e, processo para preparar os compostos | |
| BRPI0915862A2 (pt) | compostos derivados de tetraidrocinolina, processo para sua fabricação, composição farmacêutica que os compreende, uso dos mesmos e método para o tratamento ou profilaxia de diabetes e outras enfermidades | |
| BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica | |
| AR068187A1 (es) | Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv | |
| BRPI0820203A2 (pt) | Compostos de pirrdina, processo para a sua preparação, composição farmacêutica que os compreende, uso de composto e método para o tratamento e/ou profilaxia de diabetes mellitus do tipo ii e outras enfermidades | |
| BRPI0912388A2 (pt) | composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças | |
| BRPI0612254A2 (pt) | composto, formulação farmacêutica, combinação, e, processo para preparar um composto | |
| BRPI0817721A2 (pt) | Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto | |
| BRPI0812792A2 (pt) | Composição farmacêutica para tratar a diabete e o seu processo de preparação. | |
| AR075097A1 (es) | Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia | |
| BRPI0817445A2 (pt) | composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto | |
| BRPI0916949A2 (pt) | Processo para a preparação de derivados de piperazinadiona, e, uso dos compostos. | |
| BRPI0822509A2 (pt) | Fluoroalquilóxi alcanos, processo para sua produção e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |